METAVIVOR RESEARCH AND SUPPORT, INC.

Lobbying Spend

—

Filings

Firms Hired

Active Period

2016–2025

Lobbying Spend by Year

Client-reported lobbying expenses on LDA filings

Year	Lobbying Spend	Filings	Firms
2025	—	1	1
2024	—	5	1
2023	—	6	1
2022	—	4	1
2021	—	4	1
2020	—	5	1
2019	—	4	1
2018	—	4	1
2017	—	4	1
2016	—	3	1

Lobbying firms retained by this client; amounts are client-reported expenses when available

Firm Name	Reported Spend	Filings
HEALTH AND MEDICINE COUNSEL, LLC	—	40

Government entities explicitly identified as targets in LDA filings

Government Body	Filings
HOUSE OF REPRESENTATIVES	39
SENATE	39

Most frequently reported lobbying issues

Issue Code	Description	Reports
Health Issues	Health Issues	40
Budget/Appropriations	Budget/Appropriations	40

Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded

H.R. 1409115th Congress

Cancer Drug Parity Act of 2017

Cited source text and reported amounts

Social Security Disability Fairness Act Right to Try Act Healthcare Benefits & Access Healthcare Reform, Patient Protections HR 1409 HR 6114

Client expense: — · Firm income: —

Matched citations: HR 1409

H.R. 6114115th Congress

Metastatic Breast Cancer Access to Care Act

Cited source text and reported amounts

Social Security Disability Fairness Act Right to Try Act Healthcare Benefits & Access Healthcare Reform, Patient Protections HR 1409 HR 6114

Client expense: — · Firm income: —

Matched citations: HR 6114

METAVIVOR RESEARCH AND SUPPORT, INC. — Lobbying Disclosure | Poliscope